(R)-2-((tert-butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate | 352705-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-((tert-butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate
• 英文别名: [(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] 4-methylbenzenesulfonate
• CAS: 352705-03-4
• 化学式: C₁₅H₂₃NO₅S
• 分子量: 329.417
• InChiKey: KLEPSZKPAIHWIS-GFCCVEGCSA-N

物化性质

• 沸点：
  467.4±28.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-2-((tert-butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate 在 氢氧化钾 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (R)-4-[2-(tert-butyloxycarbonylamino)propyloxy]-3,5-dimethylbenzoic acid
  参考文献：
  名称：

  Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

  摘要：

  Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.

  DOI：

  10.1021/jm701359z
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 (R)-2-((tert-butoxycarbonyl)amino)propyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  [EN] BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2
  [FR] COMPOSÉS DE PYRIMIDONE BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LP-PLA2

  摘要：

  本发明涉及一种新型的抑制Lp-PLA2活性的嘧啶并[1,6-a]嘧啶-6(2H)-酮化合物，以及其制备方法、含有它们的组合物和它们在治疗与Lp-PLA2活性相关的疾病，例如动脉粥样硬化、阿尔茨海默病等方面的用途。

  公开号：

  WO2014114249A1

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• Cannabimimetic lipid amides as useful medications
  申请人：University of Connecticut

  公开号：US07161016B1

  公开（公告）日：2007-01-09

  Novel analogs of arachidonylethanolamide are presented which have higher affinities for the cannabinoid CB1 and/or CB2 receptor sites. Further, most of the analogs exhibit greater metabolic stability than arachidonylethanolamide. The improved receptor affinity and selectivity and/or greater metabolic stability make these analogs therapeutically useful as medications for relief of pain caused by cancer and nausea caused by chemotherapy, as well as for peripheral pain. The compounds may also be useful as oral and topical contraceptives, in suppression of the immune system, enhancement of appetite and in treatment of psychomotor disorders, multiple sclerosis and hypertension.

  新型的花生四烯酰乙醇胺类似物具有更高的亲和力，适用于大麻素CB1和/或CB2受体位点。此外，大多数类似物表现出比花生四烯酰乙醇胺更高的代谢稳定性。改善的受体亲和力和选择性和/或更高的代谢稳定性使这些类似物在作为药物用于缓解癌症引起的疼痛和化疗引起的恶心，以及外周疼痛方面具有治疗用途。这些化合物也可能用于口服和局部避孕药、免疫系统抑制、增强食欲以及治疗精神运动障碍、多发性硬化和高血压。
• [EN] MACROCYCLIC KINASE INHIBITORS AND THEIR USE<br/>[FR] INHIBITEURS MACROCYCLIQUES DE KINASE ET LEUR UTILISATION
  申请人：TP THERAPEUTICS INC

  公开号：WO2019126122A1

  公开（公告）日：2019-06-27

  The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

  本公开涉及某些手性二芳基大环衍生物，包含它们的药物组合物，以及使用它们治疗癌症、疼痛、神经系统疾病、自身免疫疾病和炎症的方法。
• NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS
  申请人：Bolli Martin

  公开号：US20130324579A1

  公开（公告）日：2013-12-05

  The present invention relates to pyrazole and imidazole derivatives of formula (I) wherein U, V, L, X, Y, R 1 , (R 2 ) n and (R 3 ) m and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的吡唑和咪唑衍生物，其中U、V、L、X、Y、R1、（R2）n和（R3）m以及环A如说明书所述，其制备方法，其制备的药物学上可接受的盐以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的制药组合物，特别是它们作为促进睡眠药物的用途。
• BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20150344485A1

  公开（公告）日：2015-12-03

  The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , for example atherosclerosis, Alzheimer's disease.

  本发明涉及一种新型的嘧啶[1,6-a]嘧啶-6(2H)-酮化合物，可抑制Lp-PLA2活性，其制备过程，包含它们的组合物以及它们在治疗与Lp-PLA2活性相关的疾病，例如动脉粥样硬化、阿尔茨海默病等方面的用途。